Abstract

Sodium valproate is commonly used in perioperative neurosurgery patients for seizure control and other therapeutic purposes. However, its association with hyperammonemia, a potentially life-threatening condition, remains a significant concern. This study evaluates the risk of hyperammonemia in neurosurgery patients receiving sodium valproate injection during the perioperative period. A cohort of patients undergoing neurosurgical procedures was assessed for ammonia levels pre- and post-operatively, alongside their valproate dosage and treatment duration. The results indicate that elevated ammonia levels were significantly more common in patients receiving sodium valproate, particularly at higher doses or in patients with pre-existing liver dysfunction. The study emphasizes the importance of closely monitoring ammonia levels in these patients, especially in the perioperative phase when their risk may be heightened. Recommendations for safe valproate usage and early identification of hyperammonemia are provided to mitigate potential complications.